Waterfront Wealth Inc. Reduces Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Waterfront Wealth Inc. trimmed its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 8.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,485 shares of the medical research company’s stock after selling 310 shares during the period. Waterfront Wealth Inc.’s holdings in Charles River Laboratories International were worth $643,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Handelsbanken Fonder AB raised its holdings in Charles River Laboratories International by 1.6% during the fourth quarter. Handelsbanken Fonder AB now owns 12,437 shares of the medical research company’s stock worth $2,296,000 after purchasing an additional 200 shares during the last quarter. Bryn Mawr Capital Management LLC grew its holdings in Charles River Laboratories International by 1,871.2% in the fourth quarter. Bryn Mawr Capital Management LLC now owns 35,659 shares of the medical research company’s stock valued at $6,583,000 after purchasing an additional 33,850 shares during the last quarter. Venturi Wealth Management LLC increased its position in shares of Charles River Laboratories International by 170.2% in the fourth quarter. Venturi Wealth Management LLC now owns 4,367 shares of the medical research company’s stock valued at $806,000 after buying an additional 2,751 shares in the last quarter. Empower Advisory Group LLC raised its stake in shares of Charles River Laboratories International by 2.5% during the 4th quarter. Empower Advisory Group LLC now owns 275,851 shares of the medical research company’s stock worth $50,922,000 after buying an additional 6,747 shares during the last quarter. Finally, AlphaCentric Advisors LLC purchased a new stake in shares of Charles River Laboratories International in the 4th quarter worth about $272,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. The Goldman Sachs Group dropped their target price on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a report on Thursday, January 23rd. TD Cowen raised their price objective on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research note on Monday, November 11th. Morgan Stanley cut their price objective on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 5th. UBS Group reiterated a “neutral” rating and set a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Finally, CLSA cut Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target for the company. in a report on Monday, November 18th. Three equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has issued a buy rating to the stock. According to MarketBeat, Charles River Laboratories International presently has an average rating of “Hold” and a consensus price target of $195.71.

Charles River Laboratories International Stock Up 0.5 %

Shares of NYSE:CRL opened at $163.11 on Friday. Charles River Laboratories International, Inc. has a 12-month low of $150.79 and a 12-month high of $275.00. The stock’s 50-day moving average price is $172.84 and its two-hundred day moving average price is $188.37. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The firm has a market cap of $8.34 billion, a price-to-earnings ratio of 1,087.39, a PEG ratio of 6.77 and a beta of 1.37.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.50 by $0.16. The business had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company’s quarterly revenue was down 1.1% on a year-over-year basis. During the same period last year, the company earned $2.46 earnings per share. On average, research analysts forecast that Charles River Laboratories International, Inc. will post 9.41 EPS for the current year.

Insider Buying and Selling at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 4,400 shares of the company’s stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the sale, the executive vice president now directly owns 20,013 shares of the company’s stock, valued at $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Birgit Girshick acquired 1,514 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th. The shares were bought at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the purchase, the chief operating officer now directly owns 55,058 shares in the company, valued at $9,064,198.54. The trade was a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is owned by corporate insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).